- NEGATIVE
Quarterly Revenue Gujarat Kidney and Super Sep-2026 Quarterly Revenue is Rs 9 Cr which is growth of -11.4% YoY.
- NEGATIVE
Quarterly Net Profit Gujarat Kidney and Super Sep-2026 Quarterly Net Profit is Rs 2 Cr which is growth of -22.8% YoY.
NSE: GKSL | BSE: 544666
Gujarat Kidney and Super Live Share Price Today, Share Analysis and Chart
aboutGujarat Kidney and Super Speciality Ltd. (GKSL) is a healthcare provider based in Vadodara, Gujarat, specializing in nephrology, urology, and other super-speciality medical services. The company operates a dedicated hospital facility that focuses on ... Read More
149.28-1.27(-0.84%)
731.6K
NSE+BSE Volume
NSE 20 Nov, 2026 3:31 PM
Check Before You Buy
High rank
10Positive8Negative
Pass in checklist55.6%
Check P/E Buy Sell Zone
Not enough data available
Gujarat Kidney and Super Stock Price Ranges
Day Price Range-0.8% 1 Day return | 149.3 (LTP) 147.3155.2 LowHigh |
|---|---|
Week Price Range-4.1% 1 Week return | 149.3 (LTP) 147.3163.4 LowHigh |
Month Price Range-20.5% 1 Month return | 149.3 (LTP) 147.3193 LowHigh |
52 Week Price Range31.0% 1 Year return | 149.3 (LTP) 98.4209.8 LowHigh |
Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Gujarat Kidney and Super quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|---|
| 8.6 | 9.9 | 9.7 | 9.8 | 9.7 | 11.5 | 8.1 | 8.5 | ||
Operating Exp. | 5.5 | 6.3 | 7.7 | 5.6 | 5.6 | 5.1 | 5.7 | 4.7 | |
Operating Profit | 2.6 | 3 | 1.6 | 4.2 | 4.1 | 6.3 | 2.3 | 3.8 | |
Operating Profit Margin % | 31.82% | 32.41% | 17.04% | 42.45% | 42.49% | 55.25% | 28.76% | 44.74% | |
Depr. | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.7 | |
Interest | 0.4 | 0.4 | 0.5 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | |
Profit Before Tax | 2.1 | 2.7 | 0.9 | 3.2 | 3.1 | 5.4 | 1.5 | 3.1 | |
Tax | 0.3 | 0.6 | -0.5 | 0.8 | 0.8 | 1.5 | 0.2 | 0.9 | |
Net Profit | 1.8 | 2 | 1.4 | 2.3 | 2.3 | 3.9 | 1.3 | 2.2 | |
EPS Adj. latest | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.5 | 0.2 | 0.3 | |
Net profit TTM | 7.5 | 8 | 9.9 | 9.8 | 9.7 | - | - | - | |
Basic EPS TTM | 1 | 1 | 1.3 | 1.2 | 1.2 | - | - | - | |
Earnings Transcripts | |||||||||
Results PDF | |||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Gujarat Kidney and Super Technical Analysis
Gujarat Kidney and Super EMA & SMA
Bearish-6
Bullish1
Bearish7
| 5 Day | 152.6 |
|---|---|
| 10 Day | 155.4 |
| 12 Day | 156.5 |
| 20 Day | 160.5 |
| 26 Day | 162.7 |
|---|---|
| 50 Day | 164.6 |
| 100 Day | 157.4 |
| 200 Day | 137.3 |
Gujarat Kidney and Super Delivery And Volume
Daily Avg. Delivery Volume %
20 Nov, 202646.9%
Week52.2%
Month52.1%
PositiveNeutralNegative
Gujarat Kidney and Super Resistance and Support
150.60
Pivot
| First Resistance | 153.9 |
|---|---|
| Second Resistance | 158.5 |
| Third Resistance | 161.7 |
| First Support | 146.0 |
|---|---|
| Second Support | 142.8 |
| Third Support | 138.2 |
| Day RSI | 31.4 |
|---|---|
| Day MACD | -6.2 |
| Day MFI | 16.4 |
| Day MACD Signal Line | -5.5 |
Gujarat Kidney and Super Beta
| 1 Month | 0.5 |
|---|---|
| 1 Year | - |
| 3 Month | 0.1 |
|---|---|
| 3 Year | - |
Gujarat Kidney and Super Price Change Analysis
↓-20.5%
Over 1 Month
LowHigh
147.3193.0
↓-4.6%
Over 3 Months
LowHigh
147.3209.8
↑6.3%
Over 6 Months
LowHigh
122.2209.8
↑31.0%
Over 1 Year
LowHigh
98.4209.8
Gujarat Kidney and Super Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| NEXUS GLOBAL OPPORTUNITIES FUND | Bulk | Sell | 26 Oct 2026 | 178 | 438,656 | NSE |
| NATVARSINH T CHAVDA | Bulk | Sell | 07 Oct 2026 | 192.19 | 486,148 | NSE |
| NATVARSINH T CHAVDA | Bulk | Purchase | 07 Oct 2026 | 188.97 | 471,148 | NSE |
| NATVARSINH T CHAVDA | Bulk | Sell | 05 Oct 2026 | 192.11 | 721,367 | NSE |
| QE SECURITIES LLP | Bulk | Sell | 05 Oct 2026 | 190.48 | 427,062 | NSE |
| QE SECURITIES LLP | Bulk | Purchase | 05 Oct 2026 | 192.61 | 443,342 | NSE |
| NATVARSINH T CHAVDA | Bulk | Purchase | 05 Oct 2026 | 189.10 | 721,367 | NSE |
| PRIYAL BOHRA | Bulk | Sell | 01 Oct 2026 | 193.41 | 399,546 | NSE |
| NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 01 Oct 2026 | 199.93 | 1,030,937 | NSE |
| GRT STRATEGIC VENTURES LLP | Bulk | Sell | 01 Oct 2026 | 198.93 | 570,047 | NSE |
Gujarat Kidney and Super Corporate Actions
Gujarat Kidney and Super Board Meetings
Gujarat Kidney and Super past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
104 Nov 2026 | Quarterly Results | - |
214 Aug 2026 | Quarterly Results | - |
328 May 2026 | Audited Results | - |
414 Feb 2026 | Quarterly Results | (Revised) |
Gujarat Kidney and Super Research Reports
Gujarat Kidney and Super research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 121 Dec 2025 | Hem Securities | - | - | IPO Subscribe | - | -% | |
| 218 Dec 2025 | Ventura | - | - | IPO Note | - | -% |
Gujarat Kidney and Super Corporate Filings
Gujarat Kidney and Super BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 11 Nov 2026 | Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Transcript of Earning Call conducted on 05/11/2026 | |
| 05 Nov 2026 | Q2FY27 Quarterly Result Announced for Gujarat Kidney and Super Speciality Ltd. | Healthcare Facilities company Gujarat Kidney and Super Speciality announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations: For Q2FY27, revenue from operations stood at Rs 3,809.02 lakh, reflecting a QoQ increase of 11.08% compared to Rs 3,428.92 lakh in Q1FY27 and a YoY expansion of 194.61% from Rs 1,292.88 lakh in Q2FY26. For H1FY27, it reached Rs 7,237.94 lakh, up by 156.76% YoY relative to Rs 2,818.90 lakh in H1FY26. Total income: For Q2FY27, total income achieved Rs 3,867.69 lakh, showcasing an 10.57% QoQ growth over Rs 3,497.82 lakh in Q1FY27 and a 197.13% YoY growth against Rs 1,301.67 lakh in Q2FY26. For H1FY27, total income stood at Rs 7,365.51 lakh, marking a YoY growth of 160.40% against Rs 2,828.52 lakh in H1FY26. Profit before tax (PBT): For Q2FY27, PBT arrived at Rs 862.49 lakh, higher by 23.86% QoQ from Rs 696.35 lakh in Q1FY27 and up by 113.99% YoY over Rs 403.06 lakh in Q2FY26. For H1FY27, PBT grew 35.32% YoY to Rs 1,558.84 lakh relative to Rs 1,151.97 lakh in H1FY26. Profit after tax (PAT): For Q2FY27, PAT stood at Rs 659.80 lakh, an expansion of 24.00% QoQ over Rs 532.10 lakh in Q1FY27 and an increase of 129.38% YoY compared to Rs 287.64 lakh in Q2FY26. For H1FY27, PAT rose by 43.96% YoY to Rs 1,191.90 lakh from Rs 827.96 lakh in H1FY26. Earnings per share (EPS): For Q2FY27, basic and diluted EPS stood at Rs 0.74, increasing by 12.12% QoQ against Rs 0.66 in Q1FY27 and up by 42.31% YoY from Rs 0.52 in Q2FY26. For H1FY27, basic and diluted EPS arrived at Rs 1.40, lower by 4.76% YoY relative to Rs 1.47 in H1FY26. Standalone Financial Highlights: Revenue from operations: For Q2FY27, standalone revenue from operations was reported at Rs 803.56 lakh, showing a QoQ drop of 13.06% against Rs 924.27 lakh in Q1FY27 and a YoY drop of 16.67% from Rs 964.26 lakh in Q2FY26. For H1FY27, revenue from operations declined by 18.09% YoY to Rs 1,727.83 lakh versus Rs 2,109.25 lakh in H1FY26. Total income: For Q2FY27, total income stood at Rs 855.66 lakh, down by 13.46% QoQ from Rs 988.79 lakh in Q1FY27 and lower by 11.40% YoY from Rs 965.77 lakh in Q2FY26. For H1FY27, total income came in at Rs 1,844.45 lakh, down by 12.62% YoY relative to Rs 2,110.91 lakh in H1FY26. Profit before tax (PBT): For Q2FY27, PBT stood at Rs 211.88 lakh, reducing by 20.11% QoQ relative to Rs 265.22 lakh in Q1FY27 and falling by 32.18% YoY against Rs 312.44 lakh in Q2FY26. For H1FY27, PBT fell by 44.04% YoY to Rs 477.10 lakh from Rs 852.69 lakh in H1FY26. Profit after tax (PAT): For Q2FY27, PAT arrived at Rs 177.64 lakh, dropping 12.80% QoQ over Rs 203.71 lakh in Q1FY27 and down 22.81% YoY compared to Rs 230.12 lakh in Q2FY26. For H1FY27, PAT decreased by 38.50% YoY to Rs 381.35 lakh against Rs 620.10 lakh in H1FY26. Earnings per share (EPS): For Q2FY27, basic and diluted EPS came in at Rs 0.23, down by 11.54% QoQ against Rs 0.26 in Q1FY27 and lower by 48.89% YoY from Rs 0.45 in Q2FY26. For H1FY27, basic and diluted EPS reached Rs 0.48, down by 60.66% YoY against Rs 1.22 in H1FY26. Result PDF | |
| 05 Nov 2026 | Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Newspaper Publication | Newspaper publication for Unaudited Financial Statements for the Quarter ended September 2026. | |
| 05 Nov 2026 | Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Audio recording of earning call | |
| 05 Nov 2026 | Gujarat Kidney and Super Speciality Ltd - 544666 - Announcement under Regulation 30 (LODR)-Investor Presentation | Revised presentation Uploaded for today''s Earning Con-Call. |
Gujarat Kidney and Super Documents
Gujarat Kidney and Super Earnings Call
Gujarat Kidney and Super earnings calls, including management commentary and AI-generated summaries.
Gujarat Kidney and Super Annual Reports
Gujarat Kidney and Super financials, including annual results, balance sheets, and cash flow statements.
Gujarat Kidney and Super Investor Presentations
Gujarat Kidney and Super investor presentations, including business updates, financial insights, and strategic initiatives.
Gujarat Kidney and Super - Company Profile
Gujarat Kidney and Super Management Structure
Gujarat Kidney and Super management structure with salaries, total experience, and qualifications.
Gujarat Kidney and Super Board of Directors
Gujarat Kidney and Super Board of directors with salaries, total experience, and qualifications.
About the company - Business Profile
Gujarat Kidney and Super Speciality Ltd. (GKSL) is a healthcare provider based in Vadodara, Gujarat, specializing in nephrology, urology, and other super-speciality medical services. The company operates a dedicated hospital facility that focuses on comprehensive kidney care, including diagnostics, surgical interventions, and long-term management of renal conditions. GKSL serves the regional market in Gujarat, positioning itself as a specialized center for high-end medical care in its core domains.
Key Points
- Key Facts:
- Founded Year: Incorporated in 2019 (CIN: U85300GJ2019PLC111559).
- Headquarters: Vadodara, Gujarat.
- Stock Listing: Listed on the Bombay Stock Exchange (BSE) [Stock Code: GKSL].
- Operations and Facilities: The company operates from its facility located at Plot No. 1, Jetalpur Road, Alkapuri, Vadodara. The hospital provides specialized medical services including dialysis, kidney transplants, and urological surgeries.
- Revenue Breakdown:
- For the financial year ended March 31, 2025, the company reported a total comprehensive income of ₹921.13 Lakhs on a standalone basis and ₹980.86 Lakhs on a consolidated basis.
- For the nine months ended December 31, 2025, consolidated profit after tax (PAT) reached ₹1,198.59 Lakhs, showing significant growth compared to the previous year's figures.
- Revenue is primarily generated from healthcare services, including inpatient and outpatient treatments within the Gujarat region.
- Key Products and Services:
- Nephrology: Management of acute and chronic kidney diseases, including specialized dialysis services.
- Urology: Surgical and medical treatments for urinary tract conditions.
- Super Speciality Care: Advanced diagnostic and therapeutic services for complex medical cases requiring specialized expertise.
- Strategic Initiatives and Outlook:
- The company is focused on expanding its service offerings within the super-speciality segment to capture a larger share of the tertiary healthcare market in Gujarat.
- Recent financial performance indicates a focus on scaling operations, with consolidated profits for the nine-month period ending December 2025 already exceeding the full-year figures for FY 2024-25.
- Financial Performance Summary:
- Earnings Per Share (EPS): For the year ended March 31, 2025, the basic and diluted EPS stood at ₹1.79 (standalone) and ₹1.85 (consolidated).
- Growth Trend: Net profit for the period ending December 31, 2025, showed a substantial increase, reaching ₹1,045.51 Lakhs for the owners of the company compared to ₹813.56 Lakhs in the corresponding period of the previous year.
References
